Metabolic-Associated Fatty Liver Disease in Childhood and Adolescence

• Carolyn Vespoli ^[1] ; Anoop Mohamed Iqbal ^[2] ; Mohammad Nasser Kabbany ^[1] ; Kadakkal Radhakrishnan ^[1]
  1. [1] Department of Pediatric Gastroenterology Hepatology and Nutrition, 8950 Euclid Avenue, R Building, Cleveland, OH 44195, USA
  2. [2] Department of Pediatric Endocrinology, Marshfield Clinic Health Systems, Marshfield Children’s Hospital, 3rd Floor, 3D, 1000 North Oak Avenue, Marshfield, WI 54449, USA
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 52, Nº. 3, 2023, págs. 417-430
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Metabolic-associated fatty liver disease (MAFLD) has become the most common cause for chronic liver disease among children and adolescents globally. Although liver biopsy remains the gold standard for diagnosis, emerging technology, like velocity controlled transient elastography, a noninvasive method, is being utilized to evaluate degree of fibrosis in these patients. The discovery of multiple gene polymorphisms has brought new hope for possible treatment targets. However, this research is still ongoing, making lifestyle changes and weight reduction the current mainstay of treatment. This review briefly reviews the most recent data regarding the epidemiology, pathophysiology, diagnostic modalities, and treatment of pediatric MAFLD.